TABLE 2.
Details of total eluted peptides, HLA‐I lignadome, netMHCpan4.0 predicted binding peptides, previously reported T‐cell epitopes and peptides derived from TAA proteins from the EV of breast cancer, melanoma, and myeloma cell lines
| 1. Cell lines | 2. Number of eluted peptides | 3. Number of peptides in HLA‐I ligandome (8‐15‐mer peptides) | 4. Number of netMHCpan 4.0 binding peptides | 5. Number of known immunogenic peptides identified in the study | 6. Number of peptides derived from known TAA (TAApep) |
|---|---|---|---|---|---|
| MCF7 | 43 | 18 | 5 | 2 | 0 |
| MDA‐MB‐231 | 38 | 38 | 32 | 1 | 0 |
| MDA‐MB‐361 | 67 | 67 | 35 | 1 | 4 |
| MDA‐MB‐415 | 336 | 336 | 275 | 2 | 19 |
| MDA‐MB‐453 | 127 | 120 | 115 | 2 | 5 |
| HCC 1806 | 363 | 345 | 306 | 3 | 18 |
| HCC 1395 | 534 | 533 | 502 | 2 | 32 |
| HCC 1954 | 331 | 330 | 293 | 2 | 23 |
| ESTDAB‐056 | 472 | 472 | 433 | 3 | 24 |
| RPMI 8226 | 150 | 147 | 112 | 1 | 6 |
| Total | 2461 | 2406 | 2108 | 19 | 131 |